ncRNA | Pathway | Malignancy | Type of study | Results | References |
---|---|---|---|---|---|
miR-122 | ADAM17 and cyclin G1 | HCC | In vivo | Inhibition of migration, invasion, tumorigenesis, angiogenesis, and metastasis | |
miR-21 | PTEN | HCC | In vitro and in vivo | Decreased tumor cell proliferation, migration, and invasion | [135] |
miR-34a | P53, RAS, CDK4,BCL2, c-MET, and MYC | NSCLC | Animal study | Suppressed tumor growth and enhancement in the survival rate | |
let-7b | RAS, BCL2, c-MET, and MYC | NSCLC | Animal study | Enhancement in the survival rate | [139] |
miR-200c | PRDX2, GAPB/NRF2, and SESN1 | Lung cancer | Animal study | Radiosensitivity augmentation of cancer cells | [140] |
miR-34 | P53, RAS, BCL2, c-MET, and MYC | Solid tumors | Clinical trial | Multiple immune-related severe adverse events | |
miR-29b | DNMT3B, CDK6 and MCL1 | NSCLC | Animal study | Decrease in tumor dimensions | [143] |
miR-16 | EGFR | NSCLC | Clinical trial | 5% of the patients showed partial response | [144] |
miR-125a-5p | HDAC4 | Breast Cancer | Animal study | Decrease in tumor development, metastasis, and vasculature | [146] |
miR-34a | NOTCH1 signaling pathway, Cyclin E2, and c-MYC | Breast Cancer | Animal study | Enhanced response to chemotherapy |